Abstract

Toxoplasmosis, caused by the protozoan Toxoplasma gondii, is a worldwide disease whose clinical manifestations include encephalitis and congenital malformations in newborns. Previously, we described the synthesis of new ethyl-ester derivatives of the antibiotic ciprofloxacin with ~40-fold increased activity against T. gondii in vitro, compared with the original compound. Cipro derivatives are expected to target the parasite’s DNA gyrase complex in the apicoplast. The activity of these compounds in vivo, as well as their mode of action, remained thus far uncharacterized. Here, we examined the activity of the Cipro derivatives in vivo, in a model of acute murine toxoplasmosis. In addition, we investigated the cellular effects T. gondii tachyzoites in vitro, by immunofluorescence and transmission electron microscopy (TEM). When compared with Cipro treatment, 7-day treatments with Cipro derivatives increased mouse survival significantly, with 13–25% of mice surviving for up to 60 days post-infection (vs. complete lethality 10 days post-infection, with Cipro treatment). Light microscopy examination early (6 and 24h) post-infection revealed that 6-h treatments with Cipro derivatives inhibited the initial event of parasite cell division inside host cells, in an irreversible manner. By TEM and immunofluorescence, the main cellular effects observed after treatment with Cipro derivatives and Cipro were cell scission inhibition - with the appearance of ‘tethered’ parasites – malformation of the inner membrane complex, and apicoplast enlargement and missegregation. Interestingly, tethered daughter cells resulting from Cipro derivatives, and also Cipro, treatment did not show MORN1 cap or centrocone localization. The biological activity of Cipro derivatives against C. parvum, an apicomplexan species that lacks the apicoplast, is, approximately, 50 fold lower than that in T. gondii tachyzoites, supporting that these compounds targets the apicoplast. Our results show that Cipro derivatives improved the survival of mice acutely infected with T. gondii and inhibited parasite replication early in the first cycle of infection in vitro, highlighting their therapeutic potential for the treatment of toxoplasmosis.

Highlights

  • Toxoplasma gondii, the causative agent of toxoplasmosis, is a globally spread parasite infecting approximately one third of the human population

  • The combination of pyrimethamine with sulfadiazine is the first choice of treatment for toxoplasmosis; patients often do not tolerate sulfadiazine, and long-term treatment (4–6 weeks) with this drug is commonly associated with gastrointestinal disorders that lead to treatment discontinuation

  • We showed that new prodrugs derivatives of the known antibiotic ciprofloxacin were at least 40 fold more active than the original molecule against T. gondii tachyzoites, the form of the parasite that causes acute disease [20]

Read more

Summary

Introduction

Toxoplasma gondii, the causative agent of toxoplasmosis, is a globally spread parasite infecting approximately one third of the human population. Infection of the central nervous system by this parasite is associated to encephalitis and eye disease. The vertical transmission during pregnancy can lead to abortion and congenital malformations in the newborn [1].Whereas infections by this parasite are usually asymptomatic in most individuals, T. gondii is an important opportunistic pathogen with high mortality and morbidity in immunocompromised patients [2]. The combination of pyrimethamine with sulfadiazine is the first choice of treatment for toxoplasmosis; patients often do not tolerate sulfadiazine, and long-term treatment (4–6 weeks) with this drug is commonly associated with gastrointestinal disorders that lead to treatment discontinuation. It is clear that the development of alternative or replacement treatments for toxoplasmosis is vital for improving disease treatment and control

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call